Document Detail

Combinations of low concentrations of cytokines and acute agonists synergize in increasing the permeability of endothelial monolayers.
MedLine Citation:
PMID:  8428396     Owner:  NLM     Status:  MEDLINE    
The deposition of circulating immune reactants in blood vessels, an important event in the pathogenesis of certain types of vasculitis, requires an increase in permeability in the endothelial monolayer. An in vitro model to examine the integrity of endothelial cell monolayers and their response to inflammatory mediators has been developed. Human umbilical vein endothelial cells were grown to confluence on an FITC-labelled matrix and monolayer integrity was assessed by the exclusion of a 125I-anti-FITC antibody. Alteration in endothelial monolayer permeability was associated with an increase in uptake of 125I-anti-FITC antibody, expressed as a percentage of the maximal uptake of antibody on to FITC-matrix from which endothelial cells had been stripped. We determined the effects on endothelial monolayer permeability of acute agonists (thrombin and histamine), cytokines (tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma), IL-1 and IL-4) and combinations of acute agonists and cytokines. Addition of thrombin in concentrations ranging from 0.5 to 15 U/ml led to an increased uptake of 125I-anti-FITC antibody from 2% to 15% relative to unstimulated endothelium. For other agonists and cytokines the increases in permeability were: (i) histamine (50-400 pmol/ml) increased uptake 5-22%; (ii) TNF (12.5-100 ng/ml) increased uptake 2-12%; (iii) IFN-gamma (125-250 U/ml) increased uptake 1.5-3%. IL-1 beta (50-100 U/ml) and IL-4 (50-100 U/ml) had no effect. Synergistic interactions on endothelial monolayer permeability were seen with the following combinations: (i) IL-4 (100 U/ml) and TNF (12.5 ng/ml) uptake 11%; (ii) IL-4 (100 U/ml) and IFN-gamma (125 U/ml) uptake 6.5%; (iii) TNF (12.5 ng/ml) and IFN-gamma (125 ng/ml) uptake 7%; (iv) thrombin (0.5 U/ml) and histamine (50 pmol/ml) uptake 13.5%; and (v) TNF (12.5 ng/ml) and thrombin (0.5 U/ml) uptake 8.5%. These observations suggest that interactions between cytokines and acute inflammatory mediators such as thrombin and histamine may be important in determining whether immune complexes are deposited in vessel walls. This model system may now be useful for the further investigation in vitro of the mechanisms involved in the pathogenesis of immune complex-mediated vascular damage.
H L Beynon; D O Haskard; K A Davies; R Haroutunian; M J Walport
Related Documents :
2785566 - Il-4 down-regulates il-1 and tnf gene expression in human monocytes.
23059626 - The effect of ccl3 and ccr1 in bone remodeling induced by mechanical loading during ort...
23203546 - Endothelial nitric oxide synthase is not essential for nitric oxide production by osteo...
16806176 - Immune-mediated neuroprotection of axotomized mouse facial motoneurons is dependent on ...
24861026 - Nlrp3 inflammasome activation is required for fibrosis development in nafld.
8746786 - A three-dimensional model of interferon-tau.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical and experimental immunology     Volume:  91     ISSN:  0009-9104     ISO Abbreviation:  Clin. Exp. Immunol.     Publication Date:  1993 Feb 
Date Detail:
Created Date:  1993-03-05     Completed Date:  1993-03-05     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  0057202     Medline TA:  Clin Exp Immunol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  314-9     Citation Subset:  IM    
Rheumatology Unit, RPMS, Hammersmith Hospital, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Capillary Permeability / drug effects*
Cells, Cultured
Cytokines / pharmacology*
Drug Synergism
Endothelium, Vascular / drug effects,  metabolism*
Histamine / pharmacology
Interferon-gamma / pharmacology
Interleukin-1 / pharmacology
Interleukin-4 / pharmacology
Thrombin / pharmacology
Tumor Necrosis Factor-alpha / pharmacology
Reg. No./Substance:
0/Cytokines; 0/Interleukin-1; 0/Lipopolysaccharides; 0/Tumor Necrosis Factor-alpha; 207137-56-2/Interleukin-4; 51-45-6/Histamine; 82115-62-6/Interferon-gamma; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Exposure to complement-bearing immune complexes enhances the in vitro sequestration of erythrocytes ...
Next Document:  IL-1 beta and IL-3-like activity in preterm infants.